<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147043</url>
  </required_header>
  <id_info>
    <org_study_id>2004/6746</org_study_id>
    <nct_id>NCT00147043</nct_id>
  </id_info>
  <brief_title>Adult Stem Cell Therapy in Liver Insufficiency</brief_title>
  <official_title>Adult Stem Therapy for Patients With Liver Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to determine the clinical application potential of adult stem cells we propose to
      investigate the safety and toxicity of infusing adult stem cells in the hepatic artery or
      portal vein of five patients with chronic liver insufficiency and to identify any clinical
      benefit if such occurs.

      Objectives:

        1. To assess safety and treatment related toxicities

        2. To determine clinical benefit or deterioration by monitoring changes in liver function
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The liver in an adult healthy body maintains a balance between cell gain and cell loss.
      Though normally proliferatively quiescent, hepatocyte loss such as that caused by partial
      hepatectomy, uncomplicated by virus infection or inflammation, invokes a rapid regenerative
      response to restore liver mass. This restoration of moderate cell loss and 'wear and tear'
      renewal is largely achieved by hepatocyte self-replication. More severe liver injury can
      activate a potential stem cell compartment located within the intrahepatic biliary tree,
      giving rise to cords of bipotential, so-called, oval cells within the lobules that can
      differentiate into hepatocytes and biliary epithelial cells. A third population of stem cells
      with hepatic potential reside in the bone marrow; these haematopoietic stem cells can
      contribute to the albeit low renewal rate of hepatocytes, make a more significant
      contribution to regeneration and even completely restore normal function in a murine model of
      hereditary tyrosinaemia.

      A recent abstract has suggested that an astonishingly high number of bone marrow cells (~25%
      of liver parenchyma occupied by bone marrow-derived cells) will engraft and differentiate
      into hepatocytes in a model of cirrhosis in the mouse when injected intravenously. More
      importantly, this bone marrow infusion resulted in significant improvements in liver function
      (serum albumin) within the cirrhotic animals.

      This is a safety and toxicity study in five patients with chronic liver disease. Each will
      receive autologous stem cells 10 to the sixth cells via the hepatic artery or portal vein
      under image guided scanning. Patients will be followed for a total of 60 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2005</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Autologous stem cells</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events Related to Injection</measure>
    <time_frame>Day 1 to Day 60</time_frame>
    <description>Incidence of serious adverse event related to injection with the study participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Liver Function</measure>
    <time_frame>Day 1 to Day 60</time_frame>
    <description>Number of participant that have liver function improvement in liver function</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Autologous Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <arm_group_label>Autologous Stem Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Infusion of stem cells via image guided scan</intervention_name>
    <arm_group_label>Autologous Stem Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Male or female aged from 20 years to 65 years Evidence of chronic liver failure Abnormal
        serum albumin and/or bilirubin and/or prothrombin time Unsuitable for liver transplantation
        WHO performance status &lt;2 Women of childbearing potential may be included but must use a
        reliable and appropriate contraceptive method Life expectancy of at least three months
        Ability to give informed consent

        Exclusion Criteria:

        - Patients aged below 20 years or above 65 years Pregnant or lactating women Patients with
        recent recurrent gastrointestinal bleeding Spontaneous bacterial peritonitis Evidence of
        active infection HIV infection Patients unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagy Habib, ChM FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Hospitals NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Gordon MY, Levicar N, Pai M, Bachellier P, Dimarakis I, Al-Allaf F, M'Hamdi H, Thalji T, Welsh JP, Marley SB, Davies J, Dazzi F, Marelli-Berg F, Tait P, Playford R, Jiao L, Jensen S, Nicholls JP, Ayav A, Nohandani M, Farzaneh F, Gaken J, Dodge R, Alison M, Apperley JF, Lechler R, Habib NA. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells. 2006 Jul;24(7):1822-30. Epub 2006 Mar 23.</citation>
    <PMID>16556705</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 5, 2005</study_first_submitted>
  <study_first_submitted_qc>September 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <results_first_submitted>February 25, 2019</results_first_submitted>
  <results_first_submitted_qc>October 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2019</results_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult stem cells</keyword>
  <keyword>Liver disease</keyword>
  <keyword>CD34 positive cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were sequentially recruited to the study from January 2005 to June 2005</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Autologous Stem Cells</title>
          <description>Pre-treatment with Granulocyte-Colony Stimulating Factor (G-CSF) to mobilise CD34+ cells Leukapheresis procedure to extract mobilised CD34+ cells Cultured CD34+ cells administered via hepatic artery of portal vein</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Autologous Stem Cells</title>
          <description>Male or female aged from 20 years to 65 years with evidence of chronic liver failure, abnormal serum albumin and/or bilirubin and/or prothrombin time</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Mean Age</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="41" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gender</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Count of Participants</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events Related to Injection</title>
        <description>Incidence of serious adverse event related to injection with the study participants</description>
        <time_frame>Day 1 to Day 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Stem Cells</title>
            <description>Male of Female participants aged from 20-65 years old with chronic liver failure Abnormal liver function Abnormal serum albumin and/or bilirubin and/or prothrombin time Unsuitable for liver transplantation WHO Performance status &lt;2 Women of childbearing potential may be included but must use a reliable and appropriate contraceptive method Life expectancy of at least 3 monthsAbility to give informed consent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events Related to Injection</title>
          <description>Incidence of serious adverse event related to injection with the study participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Liver Function</title>
        <description>Number of participant that have liver function improvement in liver function</description>
        <time_frame>Day 1 to Day 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Stem Cells</title>
            <description>Leukapheresis
Infusion of stem cells via image guided scan</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Liver Function</title>
          <description>Number of participant that have liver function improvement in liver function</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Autologous Stem Cells</title>
          <description>Male of Female participants aged from 20-65 years old with chronic liver failure, abnormal liver function, abnormal serum albumin and/or bilirubin and/or prothrombin time</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was limited to 5 participants, which is an insufficient number to determine true benefit. A larger Phase I/II should be undertaken to determine benefit.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Nagy Habib</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+442033138574</phone>
      <email>nagy.habib@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

